Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) issued the following statement regarding the Anesthetic and Analgesic Drug Products Advisory Committee (Advisory Committee) meeting’s vote: Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) net profit margin is 7.60% and weekly performance is -0.14%. On last trading day company shares ended up $7.23. Analysts mean target price for the company is $9.50. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)distance from 50-day simple moving average (SMA50) is 2.82%.
On June 4, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced the appointment of Douglas Williams, Ph.D., to its board of directors. Dr. Williams currently serves as executive vice president, research and development for Biogen Idec Inc. and was previously chief executive officer of ZymoGenetics, Inc. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares advanced 0.28% in last trading session and ended the day on $14.27. IRWD Gross Margin is 76.90% and its return on assets is -64.90%. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) quarterly performance is 12.01%.
Actavis plc announced that Forest Laboratories, Inc. (NYSE:FRX)has received valid consents (the “Requisite Consents”) from holders of a majority in aggregate principal amount of each series of Forest’s securities listed in the table below (the “FRX Notes”) to the elimination of Forest’s contractual registration rights obligations with respect to each series of FRX Notes (the “Proposed Amendments”) (collectively, the “Consent Solicitations”). Forest Laboratories, Inc. (NYSE:FRX) shares moved down -0.79% in last trading session and was closed at $94.37, while trading in range of $94.10 – $95.61. Forest Laboratories, Inc. (NYSE:FRX) year to date (YTD) performance is 57.20%.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals reported that the Anesthetic and Analgesic Drug Products Advisory Committee of the Food and Drug Administration (FDA) has provided an assessment of potential cardiovascular risk associated with products in the class of peripherally-active opioid receptor antagonists (PAMORAS) and recommendations regarding the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in this class for the proposed indication of opioid-induced constipation (OIC) in patients taking opioids for chronic pain. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) ended the last trading day at $113.80. Company weekly volatility is calculated as 3.48% and price to cash ratio as 18.74. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) showed a positive weekly performance of 4.52%.
On May 27, MacroGenics (MGNX) and Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) jointly announced that they have entered into an option agreement for the development and commercialization of MGD010. This product candidate incorporates MacroGenics’ proprietary platform for Dual-Affinity Re-Targeting, or DART, to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. Under the terms of the agreement, MacroGenics will receive an upfront payment of $15M and Takeda receives an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study. MacroGenics will lead all product development activities until that time. Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) shares moved up 0.43% in last trading session and was closed at $23.25, while trading in range of $23.12 – $23.32.